|
KEYNOTE-199: Pembrolizumab (pembro) for docetaxel-refractory metastatic castration-resistant prostate cancer (mCRPC). |
|
|
Honoraria - Astellas Pharma; AstraZeneca; Genentech/Roche; Pfizer; Sanofi |
Consulting or Advisory Role - Astellas Pharma; AstraZeneca; Bayer; Boehringer Ingelheim; Genentech/Roche; Merck Serono; Merck Sharp & Dohme; Pfizer; Sanofi |
Research Funding - AstraZeneca (Inst); Genentech (Inst); Sanofi (Inst) |
Patents, Royalties, Other Intellectual Property - Abiraterone Rewards to Inventors (Inst); PARP inhibitors and DNA repair defects (Inst) |
Travel, Accommodations, Expenses - Astellas Pharma; AstraZeneca; Genmab; GlaxoSmithKline; Orion; Qiagen; Sanofi; Taiho Pharmaceutical; Vertex |
|
|
No Relationships to Disclose |
|
|
Consulting or Advisory Role - AstraZeneca |
|
Jose Maria Piulats Rodriguez |
Consulting or Advisory Role - Astellas Oncology; Bristol-Myers Squibb; Clovis Oncology; Janssen; Merck; Merck Serono; Roche |
Research Funding - Bristol-Myers Squibb; Janssen; Merck Serono |
|
|
Stock and Other Ownership Interests - Compugen; ImmunExcite; NexImmune; Potenza Therapeutics; Tizona Therapeutics, Inc. |
Consulting or Advisory Role - Agenus; Astellas Medivation; AstraZeneca/MedImmune; Bristol-Myers Squibb (Inst); Compugen; Dendreon; ImmuneXcite; Janssen Oncology; Lilly; Merck; NexImmune; Pfizer; Pierre Fabre; Potenza Therapeutics; Roche/Genentech; Tizona Therapeutics, Inc. |
Research Funding - Aduro Biotech (Inst); Bristol-Myers Squibb (Inst); Compugen (Inst); Janssen Oncology (Inst) |
Patents, Royalties, Other Intellectual Property - Patents licensed to BMS (Inst); Patents licensed to Potenza Therapeutics (Inst) |
|
|
|
Consulting or Advisory Role - Bristol-Myers Squibb; Eisai; Foundation Medicine; Genentech/Roche; Prometheus; Seagen |
Speakers' Bureau - Bristol-Myers Squibb; Genentech/Roche |
Research Funding - Merck Sharp & Dohme |
|
|
|
Stock and Other Ownership Interests - Merck; Novo Nordisk |
Patents, Royalties, Other Intellectual Property - Bayer |
|
Christian Heinrich Poehlein |
|
Stock and Other Ownership Interests - Merck |
|
|
Honoraria - Astellas Pharma; AstraZeneca; Clovis Oncology; Dendreon; ESSA; Janssen Biotech; Medivation; Merck; Sanofi |
Consulting or Advisory Role - Astellas Pharma; AstraZeneca; Clovis Oncology; Dendreon; ESSA; Janssen Biotech; Medivation; Merck; Sanofi |
Research Funding - Aragon Pharmaceuticals (Inst); Astellas Pharma (Inst); AstraZeneca (Inst); Clovis Oncology (Inst); Constellation Pharmaceuticals (Inst); Dendreon (Inst); Exelixis (Inst); Genentech (Inst); Janssen Biotech (Inst); Johnson & Johnson (Inst); Merck (Inst); Millennium (Inst); Novartis (Inst); Sanofi (Inst); Tokai Pharmaceuticals (Inst) |
Patents, Royalties, Other Intellectual Property - Co-inventor of a biomarker technology that has been licensed to Qiagen |
Travel, Accommodations, Expenses - Dendreon; Medivation; Sanofi |